MVM Life Science Partners is a venture capital firm specializing in investments within the healthcare sector, focusing on early-stage and growth-stage companies in biopharmaceuticals, medical technology, diagnostics, and digital health. Founded in 1997, the firm operates globally with offices in London and Boston, leveraging its transatlantic presence to identify and support innovative healthcare businesses. MVM has raised four funds totaling over $700 million, with its largest being MVM IV, a $233 million healthcare fund closed in 2016.

The firm typically invests between $15 million and $30 million per portfolio company, supporting businesses across all stages of development, from early-stage private deals to publicly listed companies. MVM's portfolio includes notable companies such as Domantis, Heptares, Preglem, Momenta, Vascular Pathways, Beacon Endoscopic, Cara Therapeutics, Aegerion, and HBI. The firm's investment strategy combines deep sector expertise with strategic support to help portfolio companies achieve their full potential, aiming to make a significant impact on healthcare outcomes worldwide.